NEW YORK (GenomeWeb News) – Sequenom said this week that the California Technology Assessment Forum has completed an independent evaluation of the cell-free fetal DNA technology used in the Sequenom Center for Molecular Medicine's MaterniT21 Plus laboratory-developed test. According to the firm, CTAF recommended that the use of cell-free fetal DNA as a prenatal advanced screening test for fetal aneuploidy for Trisomy 21 and Trisomy 18 in high-risk women meets all five CTAF criteria for safety and efficacy and improvement in health outcomes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.